Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Cash & Equivalents (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Cash & Equivalents for 6 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 59.72% to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 59.72% decrease, with the full-year FY2024 number at $3.5 million, up 211.68% from a year prior.
  • Cash & Equivalents was $1.7 million for Q3 2025 at Ensysce Biosciences, down from $2.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $12.3 million in Q4 2021 to a low of $18034.0 in Q1 2021.
  • A 5-year average of $4.3 million and a median of $3.4 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 89.26% in 2021, then surged 46705.77% in 2022.
  • Ensysce Biosciences' Cash & Equivalents stood at $12.3 million in 2021, then plummeted by 74.34% to $3.1 million in 2022, then crashed by 64.3% to $1.1 million in 2023, then skyrocketed by 211.68% to $3.5 million in 2024, then tumbled by 52.22% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Cash & Equivalents are $1.7 million (Q3 2025), $2.2 million (Q2 2025), and $3.1 million (Q1 2025).